Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.42Last Year’s EPS
-0.35Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 42.05%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted positive advancements in the approval process for deramiocel, strong safety and efficacy data, strategic partnerships, and a solid financial position. However, the decline in revenue, increased expenses, and significant net loss cast some concerns on the financial performance. Despite these financial challenges, the strategic and clinical advancements suggest a cautiously optimistic outlook.Company Guidance
During the Capricor Therapeutics First Quarter 2025 Earnings Call, the company provided guidance on several key metrics. The CFO, A.J. Bergmann, outlined forward-looking statements regarding various aspects of the company's future, including R&D plans, regulatory filings, and financial estimates. CEO Linda Marban discussed the progress of the Biologics License Application (BLA) for deramiocel, emphasizing its potential as a first-in-class therapy for Duchenne muscular dystrophy cardiomyopathy, with a strong safety record demonstrated in over 700 infusions and 250 patients. The company highlighted the ongoing HOPE-3 Phase 3 trial, fully enrolled in the U.S., and plans for international expansion. Capricor reported a cash balance of approximately $145 million as of March 31, 2025, with a financial runway into 2027. Potential infusions of over $200 million could be achieved through milestone payments and the sale of a Priority Review Voucher. The company also detailed its commercial manufacturing preparations, European partnering opportunities, and exosome platform development. Financially, Capricor reported zero revenue for Q1 2025, with operating expenses of approximately $16.2 million for R&D and $3.1 million for general and administrative costs, resulting in a net loss of $24.4 million for the quarter.Advancements Toward Deramiocel Approval
Capricor Therapeutics is on track with their BLA for deramiocel to treat DMD cardiomyopathy, with a smooth FDA path and an upcoming advisory committee meeting seen as a positive step.
Strong Safety and Efficacy Data
Deramiocel has demonstrated a strong safety record with over 700 infusions across 250 patients and significant efficacy in slowing cardiac decline, supported by multiple clinical trials and extensions.
Strategic Appointments and Partnerships
Appointment of Dr. Michael Binks as Chief Medical Officer and active collaboration with NS Pharma for U.S. launch readiness strengthens Capricor's commercial prospects.
Robust Financial Position
Capricor has a cash balance of approximately $145 million, with a runway into 2027 and potential non-dilutive cash infusions totaling over $200 million upon FDA approval.
International Expansion Plans
Capricor is actively negotiating for European distribution with Nippon Shinyaku and planning for international expansion of their HOPE-3 trial.
---
CAPR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CAPR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $7.30 | $7.67 | +5.07% |
Mar 19, 2025 | $12.22 | $14.36 | +17.51% |
Nov 13, 2024 | $16.91 | $18.49 | +9.34% |
Aug 07, 2024 | $3.56 | $3.88 | +8.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Capricor Therapeutics (CAPR) report earnings?
Capricor Therapeutics (CAPR) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Capricor Therapeutics (CAPR) earnings time?
Capricor Therapeutics (CAPR) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CAPR EPS forecast?
CAPR EPS forecast for the fiscal quarter 2025 (Q2) is -0.42.
---